ICRM
REGN icon

Insight Capital Research & Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Insight Capital Research & Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,707
Closed -$3.1M – 113
2015
Q4 		$3.1M Sell
5,707
-5,514
-49% -$2.99M 0.9% 54
2015
Q3 		$5.22M Buy
11,221
+2,745
+32% +$1.47M 1.58% 19
2015
Q2 		$4.32M Buy
+8,476
New +$4.14M 1.14% 38

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Insight Capital Research & Management's REGN Position: Q1 2016 in Review

Insight Capital Research & Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 5,707 shares — an estimated $3.1M sold.

Insight Capital Research & Management first reported a position in REGN in Q2 2015 and held it in 3 quarters. The position peaked at $5.22M in Q3 2015. 550 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

  • Insight Capital Research & Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Insight Capital Research & Management sold 5,707 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $3.1M.
  • Insight Capital Research & Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Insight Capital Research & Management's Regeneron Pharmaceuticals position peaked at $5.22M in Q3 2015.
  • 550 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Insight Capital Research & Management's 13F filing for Q1 2016, filed 10 May 2016.